Fiber type conversion by PGC-1α activates lysosomal and autophagosomal biogenesis in both unaffected and pompe skeletal muscle

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Takikita, Shoichi ^a   Schreiner, Cynthia ^a   Baum, Rebecca ^a   Xie, Tao ^a   Ralston, Evelyn ^a   Plotz, Paul H ^a   Raben, Nina ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; GLUCOSE; PPARGC1A PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BIOGENESIS; CONTROLLED STUDY; ENZYME REPLACEMENT; FAST MUSCLE FIBER; GLYCOGEN MUSCLE LEVEL; GLYCOGEN STORAGE DISEASE TYPE 2; KNOCKOUT MOUSE; LYSOSOME; MOUSE; NONHUMAN; PHAGOSOME; PROTEIN EXPRESSION; SKELETAL MUSCLE; SLOW MUSCLE FIBER; TRANSGENIC MOUSE; ANIMAL; CYTOLOGY; DISEASE MODEL; GENETICS; GOLGI COMPLEX; HUMAN; METABOLISM; MOUSE MUTANT; MUSCLE; PHYSIOLOGY;

MUS;

ANIMALS; AUTOPHAGY; DISEASE MODELS, ANIMAL; GLUCOSE; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; GOLGI APPARATUS; HUMANS; LYSOSOMES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUSCLE, SKELETAL; MUSCLES; TRANS-ACTIVATORS;

EID: 78650785696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015239     Document Type: Article

References (58)

1. Hirschhorn R, Reuser AJ (2000) Glycogen Storage Disease Type II: Acid alpha-Glucosidase (Acid Maltase) Deficiency. In: The Metabolic and Molecular Basis of Inherited Disease McGraw-Hill. pp 3389-3420.
2. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, et al. (2006) A retrospective, multinational, multicenter study on the natural history of infantileonset Pompe disease. J Pediatr 148: 671-676.
3. Winkel LP, Hagemans ML, Van Doorn PA, Loonen MC, Hop WJ, et al. (2005) The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 252: 875-884.
4. Van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, et al. (2003) The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112: 332-340.
5. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, et al. (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68: 99-109.
6. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, et al. (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11: 210-219.
7. Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, et al. (2009) Enzyme replacement therapy with alglucosidase alfa in 44 patients with lateonset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257: 91-97.
8. Van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, et al. (2010) A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 362: 1396-1406.
9. He C, Klionsky DJ (2009) Regulation Mechanisms and Signaling Pathways of Autophagy. Annu Rev Genet 43: 67-93.
10. Mizushima N, Levine B, Cuervo AM, Klionsky DJ (2008) Autophagy fights disease through cellular self-digestion. Nature 451: 1069-1075.
11. Fukuda T, Roberts A, Plotz PH, Raben N (2007) Acid Alpha-Glucosidase Deficiency (Pompe Disease). Current Neurology and Neuroscience Reports 7: 71-77.
12. Raben N, Baum R, Schreiner C, Takikita S, Mizushima N, et al. (2009) When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease. Autophagy 5: 111-113.
13. Raben N, Takikita S, Pittis MG, Bembi B, Marie SKN, et al. (2007) Deconstructing Pompe disease by analyzing single muscle fibers. Autophagy 3: 546-552.
14. Thurberg BL, Lynch MC, Vaccaro C, Afonso K, Tsai AC, et al. (2006) Characterization of pre-and post-treatment pathology after enzyme replacement therapy for pompe disease. Lab Invest 86: 1208-1220.
15. Finck BN, Kelly DP (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116: 615-622.
16. Handschin C, Spiegelman BM (2006) Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 27: 728-735.
17. Arany Z (2008) PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev 18: 426-434.
18. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, et al. (2002) Transcriptional coactivator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418: 797-801.
19. Brault JJ, Jespersen JG, Goldberg AL (2010) PGC-1{alpha} or PGC-1{beta} (peroxisome proliferator-activated receptor {gamma} coactivator 1{alpha} or 1{beta}) overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J Biol Chem 285: 19460-19471.
20. Wenz T, Rossi SG, Rotundo RL, Spiegelman BM, Moraes CT (2009) Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci U S A 106: 20405-20410.
21. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, et al. (2006) PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophyspecific gene transcription. Proc Natl Acad Sci U S A 103: 16260-16265.
22. Raben N, Hill V, Shea L, Takikita S, Baum R, et al. (2008) Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Hum Mol Genet 17: 3897-3908.
23. Handschin C, Chin S, Li P, Liu F, Maratos-Flier E, et al. (2007) Skeletal muscle fiber-type switching, exercise intolerance, and myopathy in PGC-1alpha musclespecific knock-out animals. J Biol Chem 282: 30014-30021.
24. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17: 170-178.
25. Raben N, Schreiner C, Baum R, Takikita S, Xu S, et al. (2010) Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease. Autophagy 6: in press.
26. Raben N, Fukuda T, Gilbert AL, de Jong D, Thurberg BL, et al. (2005) Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 11: 48-56.
27. Fukuda T, Ahearn M, Roberts A, Mattaliano RJ, Zaal K, et al. (2006) Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease. Mol Ther 14: 831-839.
28. Raben N, Ralston E, Chien YH, Baum R, Schreiner C, et al. (2010) Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab 6: in press.
29. Wu JJ, Quijano C, Chen E, Liu H, Cao L, et al. (2009) Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. Aging (Albany NY) 1: 425-437.
30. Masiero E, Agatea L, Mammucari C, Blaauw B, Loro E, et al. (2009) Autophagy is required to maintain muscle mass. Cell Metab 10: 507-515.
31. Masiero E, Sandri M (2010) Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles. Autophagy 6: 307-309.
32. Schiaffino S, Sandri M, Murgia M (2007) Activity-dependent signaling pathways controlling muscle diversity and plasticity. Physiology (Bethesda) 22: 269-278.
33. Miura S, Tomitsuka E, Kamei Y, Yamazaki T, Kai Y, et al. (2006) Overexpression of peroxisome proliferator-activated receptor gamma coactivator-1alpha leads to muscle atrophy with depletion of ATP. Am J Pathol 169: 1129-1139.
34. Miura S, Kai Y, Ono M, Ezaki O (2003) Overexpression of peroxisome proliferator-activated receptor gamma coactivator-1alpha down-regulates GLUT4 mRNA in skeletal muscles. J Biol Chem 278: 31385-31390.
35. Choi CS, Befroy DE, Codella R, Kim S, Reznick RM, et al. (2008) Paradoxical effects of increased expression of PGC-1alpha on muscle mitochondrial function and insulin-stimulated muscle glucose metabolism. Proc Natl Acad Sci U S A 105: 19926-19931.
36. Michael LF, Wu Z, Cheatham RB, Puigserver P, Adelmant G, et al. (2001) Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1. Proc Natl Acad Sci U S A 98: 3820-3825.
37. Wende AR, Schaeffer PJ, Parker GJ, Zechner C, Han DH, et al. (2007) A role for the transcriptional coactivator PGC-1alpha in muscle refueling. J Biol Chem 282: 36642-36651.
38. Hawes ML, Kennedy W, O'Callaghan MW, Thurberg BL (2007) Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease. Mol Genet Metab 91: 343-351.
39. Kotoulas OB, Kalamidas SA, Kondomerkos DJ (2004) Glycogen autophagy. Microsc Res Tech 64: 10-20.
40. Kondomerkos DJ, Kalamidas SA, Kotoulas OB, Hann AC (2005) Glycogen autophagy in the liver and heart of newborn rats. The effects of glucagon, adrenalin or rapamycin. Histol Histopathol 20: 689-696.
41. Schiaffino S, Hanzlikova V (1972) Autophagic degradation of glycogen in skeletal muscles of the newborn rat. J Cell Biol 52: 41-51.
42. Schiaffino S, Mammucari C, Sandri M (2008) The role of autophagy in neonatal tissues: just a response to amino acid starvation? Autophagy 4.
43. Hickson-Bick DL, Jones C, Buja LM (2008) Stimulation of mitochondrial biogenesis and autophagy by lipopolysaccharide in the neonatal rat cardiomyocyte protects against programmed cell death. J Mol Cell Cardiol 44: 411-418.
44. Zhou J, Zhang W, Liang B, Casimiro MC, Whitaker-Menezes D, et al. (2009) PPARgamma activation induces autophagy in breast cancer cells. Int J Biochem Cell Biol 41: 2334-2342.
45. Knaevelsrud H, Simonsen A (2010) Fighting disease by selective autophagy of aggregate-prone proteins. FEBS Lett 584: 2635-2645.
46. Benton CR, Nickerson JG, Lally J, Han XX, Holloway GP, et al. (2008) Modest PGC-1alpha overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in subsarcolemmal, not intermyofibrillar, mitochondria. J Biol Chem 283: 4228-4240.
47. Taylor EB, Lamb JD, Hurst RW, Chesser DG, Ellingson WJ, et al. (2005) Endurance training increases skeletal muscle LKB1 and PGC-1alpha protein abundance: effects of time and intensity. Am J Physiol Endocrinol Metab 289: E960-E968.
48. Van Rooij E, Quiat D, Johnson BA, Sutherland LB, Qi X, et al. (2009) A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 17: 662-673.
49. Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, et al. (1998) Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 273: 19086-19092.
50. Zhu Y, Li X, McVie-Wylie A, Jiang C, Thurberg BL, et al. (2005) Carbohydrate-remodeled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem J.
51. Raben N, Shea L, Hill V, Plotz P (2009) Monitoring autophagy in lysosomal storage disorders. Methods Enzymol 453: 417-449.
52. Tamaki H, Yamashina S (1994) Improved method for post-embedding cytochemistry using reduced osmium and LR white resin. J Histochem Cytochem 42: 1285-1293.
53. Douillard-Guilloux G, Raben N, Takikita S, Batista L, Caillaud C, Richard E (2008) Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Hum Mol Genet 17: 3876-3886.
54. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, et al. (2009) Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 39: 591-602.
55. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T (2004) LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci 117: 2805-2812.
56. Kihara A, Kabeya Y, Ohsumi Y, Yoshimori T (2001) Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network. EMBO Rep 2: 330-335.
57. Chinnadurai G, Vijayalingam S, Gibson SB (2008) BNIP3 subfamily BH3-only proteins: mitochondrial stress sensors in normal and pathological functions. Oncogene 27(Suppl 1): S114-S127.
58. Ralston E, Ploug T, Kalhovde J, Lomo T (2001) Golgi complex, endoplasmic reticulum exit sites, and microtubules in skeletal muscle fibers are organized by patterned activity. J Neurosci 21: 875-883.